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Interaction between diabetic status and lesion complexity for 1-year safety
and efﬁcacy outcomes
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Efﬁcacy
endpoints
TLR 4.6% 4.8% 0.96
(0.64,1.44
8.0% 4.5% 1.80
(1.39,2.33)
0.01
TVR 7.4% 6.8% 1.13
(0.81, 1.58)
10.6% 5.9% 1.81
(1.45, 2.27)
0.02
Safety
endpoints
Cardiac
dearh or MI
3.6% 2.1% 1.71 (1.00-
2;93)
5.7% 4.7% 1.22
(0.93,1.60)
0.28
Stent
Thrombosis
0.7% 0.3% 2.32 (0.60,
8.97)
1.7% 0.9% 1.87 (1.05,
3.32)
0.78
Independent Predictors of Stent Thrombosis at 1 Year
HR 95% CI p Value
Clinical variables
Hypertension 3.93 1.53 – 10.12 0.005
STEMI vs NSTEMI/
UA
2.72 1.46 – 5.06 0.002
History of
peripheral vascular
disease
2.18 1.05 – 4.51 0.040
Angiographic/
procedural
variables
Ejection fraction
40%
2.41 1.15 – 5.00 0.020
IVUS-guided
stenting
0.49 0.24 – 0.90 0.045
Later vs early
generation DES
0.54 0.29 – 1.00 0.050
Other variables
Premature DAPT
discontinuation
5.16 2.57 – 10.34 <0.001
VerifyNow P2Y12
PRU >208
2.92 1.57 – 5.42 <0.001
Separate Cox models were used for clinical, angiographic/procedural, and other variables
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 1:00 PM–3:00 PM
O
R
A
L
SConclusions: ST within 1 year occurs inw1% of ACS patients treated with DES and
is associated with high rates of myocardial infarction and mortality. Strategies that
may reduce ST in ACS patients include the use of more potent ADP antagonists, better
strategies to achieve DAPT adherence, the use of later generation DES, and optimi-
zation of post-stent results with IVUS.
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Background: Previous studies have shown conﬂicting results in regard to efﬁcacy
outcomes of drug-eluting stents (DES) in patients with and without diabetes mellitus
(DM). Little is known on the impact of baseline lesion complexity on clinical
outcomes in these patients.
Methods: Patient-level data from 18 prospective randomized DES trials were pooled
(ACUITY; COMPARE; C-SIRIUS; ENDEAVOR 2; ENDEAVOR 3; ENDEAVOR
4; E-SIRIUS; HORIZONS-AMI; RAVEL; SIRIUS; SPIRIT 2; SPIRIT 3; SPIRIT 4;
TAXUS 1; TAXUS 2; TAXUS 4; TAXUS 5; TAXUS 6). Propensity-adjusted
outcomes according to the presence of DM and lesion complexity (ACC/AHA class
A/B1 vs. B2/C).
Results: Among 18,441 randomized patients, 3,467 (19%) had DM. Pts with vs.
without DM had higher 1-year rates of TLR (HR [95%CI] ¼ 1.34 [1.05, 1.70]), TVR
(HR [95%CI] ¼ 1.40 [1.15, 1.72]) and TVR non-TLR (HR [95%CI] ¼ 1.62 [1.14,
2.31). The 1-year rates of cardiac death or myocardial infarction (MI) were also higher
in DM (HR [95%CI] ¼ 1.40 [1.09, 1.81]). As shown in the Table, an interaction was
present between DM status and ACC/AHA lesion class on the need for repeat
revascularization after DES. There was no interaction between DM status and ACC/
AHA lesion class on safety endpoints.
Conclusions: In the DES era, the rates of TLR and TVR after PCI of non-complex
lesions are similar in DM and non-DM patients, whereas complex lesions still have
higher repeat revascularization rates if DM is present. Compared to non-DM, DM
patients continue to have higher rates of clinical restenosis in complex lesions, and of
cardiac death and MI in all patients. Despite advances in DES, new strategies are
needed for the diabetic patient.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-20
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Background: This article reports the 2-year clinical outcomes of the abluminal
groove-ﬁlled biodegradable polymer sirolimus-eluting stent (SES) FIREHAWK
(MicroPort Medical, Shanghai, China) compared with the everolimus-eluting stent
(EES) XIENCE V in the randomized TARGET I trial.
Methods: A total of 458 patients with single de novo native coronary lesions
<¼24 mm in length and a coronary artery >¼2.25 to <¼4.0 mm in diameter were
enrolled in the TARGET I study, a prospective, randomized, non-inferiority trial. The
primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The
secondary endpoint, target lesion failure (TLF), was deﬁned as the composite of
cardiac death, target vessel myocardial infarction (TVMI), or ischemia-driven target
lesion revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6- and 12-
month, and annually up to 5 years for all enrolled patients. All adverse clinical events
were adjudicated by an independent committee.
Results: The 9-month in-stent LLL of the FIREHAWK was comparable to the
XIENCE V group (0.130.24 mm vs. 0.130.18 mm, p¼0.94; difference and 95%
conﬁdence interval 0.00 [-0.04, 0.04] mm; p for non-inferiority <0.0001). After 2
years, the TLF rates were 2.7% and 2.6% in FIREHAWK and XIENCE V group,
respectively (p ¼ 0.97). Between 1 year and 2 years, only 1 new iTLR was occurred
in each group, with no additional cardiac death and TVMI. No deﬁnite / probable
stent thrombosis was observed in both groups at 2 years. The major results are shown
in the table.acts/ORAL/Bare Metal and Drug-Eluting Stents B7
